A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

NCT06244771 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

403

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors With KRAS G12C Mutations
Solid Tumor, Adult
Unresectable Solid Tumor
Metastatic Solid Tumor
Non Small Cell Lung Cancer
Colorectal Cancer
KRAS G12C
Pancreatic Cancer

Interventions

DRUG: FMC-376

Sponsor

Frontier Medicines Corporation